Table 1.
Theranostics under preclinical development and in clinical trials for pediatric cancers.
| Molecular Target | Pediatric Cancer | Theranostic | Development Phase | Pediatric Clinical Trial Number | Refs | |
|---|---|---|---|---|---|---|
| Norepinephrine | Neuroblastoma | [123/131I]mIBG, | Routine Care | Multiple Trials | (14–16, 22–25, 78), | |
| Transporter | [18F]mFBG, | Phase I/II | NCT02348749 | (29, 30) | ||
| [211At]mABG | Preclinical | (34) | ||||
| Somatostatin | Neuroblastoma | [68Ga]DOTATATE, | Phase I/II | NCT04040088 | (39–42), | |
| Receptor 2A | [177Lu]DOTATATE, | Phase I/II | ||||
| [68Ga]OPS202, | Phase I/II | |||||
| [177Lu]OPS201, | Phase I/II | |||||
| C-X-C Chemokine | Neuroblastoma | [68Ga]Pentixafor, | Early Phase I | (48, 50), | ||
| Receptor 4 | Rhabdomyosarcoma | [177Lu]Pentixather | Early Phase I | |||
| Glioblastoma | ||||||
| ALL &AML | ||||||
| Fibroblast | Glioblastoma | [68Ga]FAPI, | Phase I/II | (56, 57), | ||
| Activation Protein | [177Lu]FAPI | Preclinical | ||||
| Ganglioside D2 | Neuroblastoma | [89Zr]Dinutuximab, | Preclinical | (68–70) | ||
| Osteosarcoma | [68Ga]WHWRLPS | Preclinical | ||||
| Glioblastoma | ||||||
| B7-H3 (CD276) | Pontine Glioma | [124/131I]8H9 | Phase I/II | NCT03275402/ | (75, 76), | |
| Neuroblastoma | (omburtamab) | NCT01502917/ | ||||
| NCT04022213 |